HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.

AbstractBACKGROUND:
Research on pharmacotherapy received by individuals with body dysmorphic disorder (BDD), a relatively common and impairing disorder, is very limited.
METHODS:
We examined past and current pharmacotherapy received by 151 individuals with BDD who were recruited from diverse sources.
RESULTS:
72.9% of subjects had received psychotropic medication. The most common type ever received was an SRI (65.6%), followed by non-SRI antidepressants (41.1%) and benzodiazepines (27.2%). Subjects with greater lifetime impairment due to BDD were more likely to have received pharmacotherapy, and subjects with lifetime OCD or greater lifetime impairment due to BDD were more likely to have received an SRI specifically. Subjects revealed their BDD symptoms to only 41.0% of pharmacotherapists. Only 12.9% of SRI trials were considered optimal for BDD, and an additional 21.5% were considered minimally adequate. SRI trials that were considered optimal or at least minimally adequate for BDD were associated with greater improvement in BDD and less severe current BDD symptoms than non-optimal or inadequate SRI trials.
CONCLUSIONS:
A high proportion of individuals with BDD receive pharmacotherapy, primarily SRIs, although most SRI trials appear inadequate for BDD. SRI treatment that was considered adequate was associated with greater improvement in BDD and less severe BDD symptoms.
AuthorsKatharine A Phillips, Maria E Pagano, William Menard
JournalAnnals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists (Ann Clin Psychiatry) 2006 Oct-Dec Vol. 18 Issue 4 Pg. 251-7 ISSN: 1040-1237 [Print] United States
PMID17162625 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Anxiety Agents
  • Antidepressive Agents
  • Psychotropic Drugs
  • Serotonin Uptake Inhibitors
  • Benzodiazepines
Topics
  • Adult
  • Anti-Anxiety Agents (therapeutic use)
  • Antidepressive Agents (therapeutic use)
  • Benzodiazepines (therapeutic use)
  • Cognitive Behavioral Therapy
  • Combined Modality Therapy
  • Comorbidity
  • Delusions (diagnosis, drug therapy, psychology)
  • Depressive Disorder, Major (diagnosis, drug therapy, psychology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Obsessive-Compulsive Disorder (diagnosis, drug therapy, psychology)
  • Psychotropic Drugs (therapeutic use)
  • Selective Serotonin Reuptake Inhibitors (therapeutic use)
  • Somatoform Disorders (diagnosis, drug therapy, psychology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: